• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Cytosorbents Corporation

    4/17/25 2:22:59 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care
    Get the next $CTSO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    CytoSorbents Corporation

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    23283X206

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    23283X206


    1Names of Reporting Persons

    Skylands Capital, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    WISCONSIN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,002,702.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,002,702.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,002,702.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.8 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CytoSorbents Corporation
    (b)Address of issuer's principal executive offices:

    305 College Road East Princeton, NJ 08540
    Item 2. 
    (a)Name of person filing:

    Skylands Capital, LLC
    (b)Address or principal business office or, if none, residence:

    1200 N Mayfair Rd, Suite 250 Milwaukee, WI 53226
    (c)Citizenship:

    Wisconsin Limited Liability Company
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    23283X206
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,002,702
    (b)Percent of class:

    4.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    3,002,702

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    3,002,702

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Skylands Capital, LLC
     
    Signature:/s/ Virginia E. Shaffar
    Name/Title:Virginia E. Shaffar Vice President & Treasurer
    Date:04/16/2025
    Get the next $CTSO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTSO

    DatePrice TargetRatingAnalyst
    9/7/2023$4.00Buy
    B. Riley Securities
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $CTSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

      SC 13G/A - Cytosorbents Corp (0001175151) (Subject)

      11/14/24 4:48:32 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Cytosorbents Corporation

      SC 13G - Cytosorbents Corp (0001175151) (Subject)

      2/14/24 4:42:32 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Cytosorbents Corporation

      SC 13G - Cytosorbents Corp (0001175151) (Subject)

      2/14/24 9:00:04 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    SEC Filings

    See more
    • Cytosorbents Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cytosorbents Corp (0001175151) (Filer)

      5/1/25 4:25:40 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cytosorbents Corporation

      SCHEDULE 13G/A - Cytosorbents Corp (0001175151) (Subject)

      4/30/25 10:59:27 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Cytosorbents Corporation

      DEFA14A - Cytosorbents Corp (0001175151) (Filer)

      4/23/25 4:28:50 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Leadership Updates

    Live Leadership Updates

    See more
    • CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

      Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller.  Ms. Grossman joins CytoSorbents with over 25 years of accomplished finance and accounting experience in global, publicly-traded companies. 

      4/17/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

      PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing approval, Mr. Shannon will lead the marketing strategy and execution for DrugSorb™-ATR in the U.S. and Canada. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and di

      4/14/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

      PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red

      11/11/24 7:30:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Financials

    Live finance-specific insights

    See more
    • CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

      PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approv

      4/29/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

      2024 marked by strong commercial execution and improved operating leverageCompany continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheetStrengthening of clinical portfolio across cardiac surgery and critical care in 2025 with new presentations and publications The Company has now adopted the standard accounting convention of reporting Revenue to only include Product Sales. Grant Income is no longer reported as a component of RevenuePRINCETON, N.J., March 31, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening

      3/31/25 4:15:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

      The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has rescheduled its previously announced fourth quarter and full year 2024 earnings call to allow more time to complete the annual financial audit prior to the earnings release.

      3/21/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on CytoSorbents with a new price target

      B. Riley Securities initiated coverage of CytoSorbents with a rating of Buy and set a new price target of $4.00

      9/7/23 8:13:32 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on CytoSorbents with a new price target

      B. Riley Securities resumed coverage of CytoSorbents with a rating of Buy and set a new price target of $10.00

      10/14/21 7:58:45 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CytoSorbents Provides Regulatory Update for DrugSorb-ATR

      PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device.  DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping the antiplatelet drug Brilinta® (ticagrelor, AstraZeneca), a commonly used blood thinner. CTSO) is a leader in the treatment of life-threatening conditions using blood purific

      5/1/25 4:15:00 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

      PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approv

      4/29/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

      PRINCETON, N.J., April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA). CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, Cyt

      4/21/25 7:00:00 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mariani Peter J bought $19,294 worth of shares (20,000 units at $0.96), increasing direct ownership by 5% to 401,363 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/16/24 7:00:11 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Mariani Peter J bought $27,975 worth of shares (31,363 units at $0.89), increasing direct ownership by 9% to 381,363 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/13/24 8:00:13 AM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Sobel Alan D. bought $30,001 worth of shares (22,557 units at $1.33), increasing direct ownership by 28% to 101,857 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      12/15/23 4:35:14 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care

    $CTSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bator Michael G. increased direct ownership by 7% to 151,273 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      3/4/25 9:00:21 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • President and COO Capponi Vincent increased direct ownership by 2% to 677,168 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      2/26/25 7:29:54 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Mariani Peter J increased direct ownership by 8% to 466,613 units (SEC Form 4)

      4 - Cytosorbents Corp (0001175151) (Issuer)

      2/26/25 7:28:35 PM ET
      $CTSO
      Medical/Dental Instruments
      Health Care